AstraZeneca and Mitsubishi Tanabe Pharma Collaborate in Diabetic Nephropathy - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

AstraZeneca and Mitsubishi Tanabe Pharma Collaborate in Diabetic Nephropathy


AstraZeneca and Mitsubishi Tanabe Pharma Corporation (MTPC) have entered a three-year research collaboration in the area of diabetic nephropathy (failure of the kidney function due to diabetes). The aim of the research collaboration is to validate and progress novel research targets and molecules into clinical development.

The collaboration will span from target selection up to the delivery of small-molecule candidate drugs. Targets from each company’s early research portfolios have been identified as approaches of common interest and additional targets may be included under the collaboration at a later stage, if mutually desired. The research will be performed in parallel at AstraZeneca’s Cardiovascular and Metabolic Disease Innovative Medicines Unit (CVMD iMed) in Mölndal, Sweden, and at MTPC’s facilities in Japan. The companies believe that the collaboration will yield high quality candidate drugs much faster than working alone. There is no financial commitment for the research involved, and each party will contribute equal resource at their own cost.

“Diabetes is a core therapeutic area for AstraZeneca and a key growth platform for the company. With current approaches to diabetic nephropathy resulting in patients needing expensive and limited treatment options, such as dialysis or kidney transplantation, there’s a significant unmet clinical need," said Marcus Schindler, head of AstraZeneca's CVMD iMed, in a press release. "This collaboration will allow us to focus on early stage programs and generate decision-making data faster than working alone, ultimately providing a quicker expansion of our diabetic nephropathy portfolio for the treatment of chronic kidney disease."

Source: AstraZeneca

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here